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Background: Specific pathogenic bacteria have been implicated in recurrent aphthous stomatitis (RAS), a
chronic inflammatory condition characterised by ulcerations in the oral mucosa. However, the aetiology
behind this condition still remains unclear.
Objective: The buccal microbiota of patients with RAS was compared to that of control subjects to investigate
its potential role for this condition.
Design: Buccalswabswereobtainedfromnon-ulcerative areasof60 patients,ofwhom42patientshadlesionsatthe
time of sampling, and 60 healthy age- and gender-matched controls. Bacterial DNAwas extracted and analysed by
Terminal-RestrictionFragmentLengthPolymorphism,usingenzymaticdigestionofthepolymerasechainreaction-
amplified 16S rRNA gene, yielding a series of peaks, each representing a bacterial taxon.
Results: Two peaks, 60 and 489, were more prevalent in patients with RAS than controls. Conversely, peaks
58 and 490 were less common in patients than controls. When the patients were divided into subgroups, we
found that the observed differences in peak-pattern were related to the presence of lesions during sampling.
Conclusions: The microbiota of the non-inflamed buccal mucosa differed between patients and controls. The
differences were most pronounced in patients who presented with lesions during sampling, suggesting that a
disturbance in the normal buccal microbiota triggers the presence of lesions or that presence of lesions alters
the microbiota.
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ecurrent aphthous stomatitis (RAS) is a chronic
inflammation of the oral mucosa characterised
by recurrent ulcerations that affect primarily the
non-keratinised mucosa. RAS is one of the most common
oral mucosal disorders, with a prevalence of approxi-
mately2%,althoughgeographicalvariationsinprevalence
have been identified (1). Currently, no curative therapy is
available and treatment strategies are aimed at reducing
the discomfort caused by ulcerations. The aetiology of
RAS remains unknown. Viruses and bacteria (2) as well
as genetic susceptibility (3) have been implicated in this
disease.
Bacteria may contribute to the pathogenesis of RAS,
acting either as pathogens or as the source of antigens that
induce the production of antibodies, which can cross-react
with oral mucosal keratinocytes. Barile et al. proposed
Streptococcus sanguinis 2A as a causative agent of RAS
(2), where the unstable L-form of this bacterium would
convert to a transient pathogenic form responsible for
disease progression while the stable L-form would be
inactive. This could explain the recurrent nature of
aphthous stomatitis. Other streptococcal species, such
as Streptococcus mitis (4) and Streptococcus oralis (5),
have been suspected to provoke development of RAS.
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(page number not for citation purpose)Furthermore, a 65-kDa heat shock protein released by
various streptococcal strains was shown to cross-react
with peptides in the oral epithelium, suggesting that
streptococci can trigger lesions based on an autoimmune
reaction (6). Helicobacter pylori has also been found in
RAS lesions (7). H. pylori causes duodenal ulcers with
clinical features similar to those observed in RAS. How-
ever, the pathogenic roles of these different bacteria in RAS
have not been resolved to date, and it remains to be proven
that this condition has a microbiological aetiology (8).
The microbial communities in the oral cavity form a
complex commensal microbiota. Disruption of the gut
microbiota has been implicated in the development of gut
mucosal inflammation in inflammatory bowel diseases
(9, 10). To date, the contribution of the normal oral
microbiota in RAS has not been investigated.
Traditionally, culture-based methods have been used
to study bacterial communities. More recently, molecular-
based methods have enabled the analysis of non-cultivable
bacteria. Terminal-Restriction Fragment Length Polymor-
phism (T-RFLP) is a technique that is based on varia-
tions in the 16S rRNA gene, as revealed by restriction
enzyme digestion patterns (11). The method provides a
culturing-independent, rapid, sensitive and reproducible
fingerprint of complex microbial communities.
The aim of this study was to characterise the oral
microbiota of patients with RAS using T-RFLP. In con-
trast to previous studies, in which the microbiota was
sampled in the ulcerative lesion (12, 13) we focused on
the microbiota of the non-inflamed buccal mucosa in
patients with RAS. Patients with or without ulcerations
at the time of sampling were included, to determine
whether the microbiota changes in relation to disease
activity. The present study is the first to investigate if the
profile of the oral microbiota in patients with RAS is
different compared to healthy control subjects.
Subjects and methods
Study population
In this case-control study, 60 patients with RAS were
enrolled, together with 60 healthy, age-and gender-
matched controls. All the patients were selected from the
referral population at the Clinic of Oral Medicine, Public
Dental Health, Gothenburg, the Region Va ¨stra Go ¨taland
of Sweden, while the control subjects were recruited from
localPublicDental Healthclinics acrosstheRegion,inthe
period 2010 2012. Most of the patients visited the clinic
regularlyforatleastsixmonthsforcheck-ups.Asallofthe
control subjects visited their local Public Dental Health
clinics for annual examinations, all of the subjects in the
study were fully characterised. Patients and controls were
not related or shared a common household.
The patients were selected randomly in that all indivi-
duals who fulfilled the inclusion criteria were offered
to participate; the episodes of aphthous ulcers should
occur at least once a month. Exclusion criteria were use
of antibiotics or antibacterial mouth rinses during the
previous month or drugs for the treatment of ulcers in
the previous six months. Further exclusion criteria were
other types of oral mucosal lesions, smoking or excessive
consumption of alcohol (alcohol intake more than three
times weekly). Of the 60 patients with RAS, 24 used some
form of medication regularly, for other conditions than
their mouth ulcers. Characteristics of the patients are
listed in Table 1 and Supplementary Table 1. Overall
dental health was not examined in detail, although no
patient suffered from any severe caries or periodontal
disease. All patients were categorised as ‘minor RAS’ or
‘major RAS’ (N 30 per group), based on whether the
lesion had adiameterofB10mm(minorRAS)or ]10mm
(major RAS), in accordance with the standard nomencla-
ture. The control subjects did not suffer from any systemic
or oral disease, were not taking any medication, had not
usedantibacterialmouthrinsesorantibioticsinthemonth
prior to sampling, did not suffer from allergies, did not
smoke, and consumed alcohol in moderation (alcohol
intake of maximum three times weekly) or not at all.
All the clinical data concerning the patients were re-
corded as single data entries in the web-based Medview
programme (14).
The guidelines of the World Medical Association
Declaration of Helsinki were followed. The Ethical Re-
view Board in Gothenburg approved the study, and
written informed consent was obtained from all the
patients and control subjects (Dr no: 386-10).
Sampling procedures
Sampling of the buccal mucosa was carried out with
a sterile swab (Isohelix/Cell Projects Ltd, Kent, UK).
Sampling was performed when the patients had the pos-
sibility to visit the clinic. For this reason, some patients
had active ulcers at the time of sampling whereas others
did not. Thus, one or several aphthous ulcerswere present
in the oral mucosa in 42 cases (25 minor RAS and 17
major RAS) while 12 patients had no ulcers at sampling
(five minor RAS and seven major RAS). For six of the
patients in the major RAS group, it was not clear from
their oral medical journals whether or not they presented
withanulceruponsampling.Thesamplesweretakenfrom
the buccal mucosa at a location distant from the ulcers.
The participants were requested not to have brushed their
teeth or consumed any food or beverage within an hour
before sampling. Two dentists participated in the collec-
tion of samples using a standardised technique, accord-
ing to the protocol of the manufacturer (Isohelix/Cell
Projects Ltd, Kent, UK).
T-RFLP analysis
This method iswidely used tostudy bacterial communities
in complex environments, such as the oral cavity, using
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gene contains sequences that are highly conserved among
bacteria, and variable regions that differ in sequence
between bacterial species. In T-RFLP, the 16S rRNA
gene is amplified and the terminal fragment fluorescently
labelled during the polymerase chain reaction (PCR)
reaction, thereby facilitating its detection. The PCR
products are then digested with a specific restriction
enzyme, and the fragments are detected. Each fragment
generates an individual peak of a certain size, a T-RF,
which represents a specific bacterial taxon, while the
pattern of peaks reveals the bacterial profile of an
individual. Generally, T-RFLP permits differentiation to
the genus level and sometimes to the species level (15). At
least eight streptococcal species can be distinguished using
T-RFLP.
DNA extraction
Buccal swabs were stored at room temperature after
sampling. Thereafter bacterial DNA extraction was per-
formed by LGC Genomics, Germany, using the sbeadex
†
Forensic Kit for the preparation of nucleic acids (LGC
Ltd, Middlesex, UK).
Amplification
The T-RFLP analysis was set-up and performed as
described previously (15) (Fig. 1a). In brief, bacterial
16S rRNA genes were amplified using the universal
primers ENV 1 (5?-6-FAM-AGA GTT TGA TII TGG
CTC AG-3? (for Escherichia coli nucleotides (nt) 8-27)
and ENV 2 (5?-CGG ITA CCT TGT TAC GAC TT-3?
(for E. coli nt 1511-1492) (16), with the forward primer
being fluorescently labelled with 6-FAM at the 5? -end.
The PCR mixture contained 100 ng DNA, 25 ml Hot
Start Taq Master Mix (2.5 U Taq DNA polymerase, 1.5
mM MgCl2, 200 mM dNTP) (Qiagen, Hilden, Germany),
0.3 mM primer, 1 mM MgCl2, and H2O to a final volume
of 50 ml for each buccal swab sample. The PCR reaction
was performed in an Eppendorf Mastercycler Gradient
(Eppendorf, Hamburg, Germany) using the following
steps: initial activation of Taq polymerase at 958Cf o r
15 min; 25 cycles of 948C for 1 min; 508C for 45 s; 728C
for 2 min; and a final extension step at 728C for 7 min.
Negative controls that contained all the PCR reagents
were included throughout the analysis, to detect poten-
tial DNA contamination. Each buccal swab sample
was analysed in three independent PCRs and then the
triplicate PCR products were pooled.
Restriction enzyme digestion and fragment analysis
PCR products were purified using the QIAquick PCR
Purification kit (Qiagen, Hilden, Germany). For each
sample, 100 ng of the 16S amplicon were digested with
16 U MspI (New England Biolabs, Ipswich, replace with
state) in a final volume of 5 mla t3 7 8C for 5 hours. The
reaction was stopped by incubating the samples at 658C
for 20 min. The digested, fluorescently labelled fragments
were detected using the ABI PRISM 310 genetic analyser
(Applied Biosystems, Carlsbad, CA) with an injection
time of 5 s and separation for 50 min at 15 kV in a
Performance Optimized Polymer (Pop) 4 gel. A mixture
of 1 ml of digested 16S amplicon, 9 ml of formamide,
Table 1. Clinical characteristics of patients with recurrent aphthous stomatitis (RAS) and healthy gender- and age-matched
controls
Characteristic RAS patients (N 60) Controls (N 60)
Age (years)
Median age 23 26
Range 6 68 7 70
N % N %
Gender
Females 36 60 36 60
Lesion size
Minor RAS
a 30 50 0 0
Major RAS
b 30 50 0 0
Lesion at sampling
Patients with lesion at sampling
c 42 70 0 0
Minor RAS patients with lesion at sampling 25 83 0 0
Major RAS patients with lesion at sampling 17 57 0 0
Medication at sampling
Patients on medication at sampling
d 24 40 0 0
aLesion diameterB10 mm.
bLesion diameter ]10 mm.
cRAS exhibits a recurrent pathology and some patients presented with a lesion at the time of sampling.
dIncludes all types of medication, apart from those used to treat RAS.
Oral microbiota of patients with RAS
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Biosystems) was denatured at 958C for 3 min and then
placed immediately on ice. Each sample was analysed
three times. The fragment lengths were determined with
the GeneMapper ver. 4 software (Applied Biosystems)
using the Local Southern Method.
Identification of bacterial taxa (genus/species level)
associated with RAS
The In silico software (http://insilico.ehu.es/) was used for
the identification of peaks that were previously correlated
with RAS (17). This online database was used for simu-
lation of enzymatic digestion, so as to identify the RAS-
correlated bacterial taxa from the peaks generated by the
T-RFLP, that is, T-RFs. The positions of the cleavage
sites and the sizes of the fragments generated by the MspI
enzyme from the 16S rRNA genes were determined.
Statistical analysis
The thresholds employed to identify ‘true’ T-RFs from the
background ‘noise’ were set statistically within a fragment
length in the range of 28 1,000 bp (18). In brief, the
data were standardised by dividing the area of each peak
by the total peak area of that particular sample. The
standarddeviation (SD) of the dataset was then computed
assuming that the true mean was zero. Peaks with an area
greater than the mean plus three SDs were considered
true signals, and therefore retained for further analyses.
This processwasreiterated until no additional ‘true’ peaks
were identified. Fragments that differed by no more
than91 bp in different analysis were considered to be
identical. The analysiswas performedwith the Perl (http://
www.perl.org/get.html) and R (http://cran.r-project.org/
bin/windows/base/old/2.9.2/) software packages. Samples
were run in triplicate, and only those fragments that were
Fig. 1. No difference in bacterial diversity between patients with recurrent aphthous stomatitis (RAS) and control subjects.
(a) The Terminal-Restriction Fragment Length Polymorphism (T-RFLP) method is based on variations in 16S rRNA genes
within bacterial populations. Bacterial DNAwas prepared from swabs taken from the intact buccal mucosa of the study subjects
and used as template for PCR ampliﬁcation of 16S rRNA genes using universal primers. The PCR products were digested with
a restriction enzyme that yields a fragment ﬁngerprint representative of a speciﬁc bacterial species, and the cleaved PCR
products were detectedwith a fragment analyser. The size of each fragment/height of each peak is representative of an individual
bacterial genus/species. Richness, calculated as (b) the number of peaks in each individual or (c) by Shannon’s Index. (d)
Evenness, calculated by Shannon’s Evenness Index. Horizontal bars indicate median values and each symbol represents a single
individual. The data was analysed with a Mann-Whitney U-test.
Maria Bankvall et al.
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considered; the peak sizes and areas from the duplicate/
triplicate runs were averaged.
Multivariate analysis (SIMCA P  ver. 13; Umetrics
AB, Umea ˚, Sweden) was used to project associations
for the microbial patterns. This was achieved using a
Partial Least Squares-discriminant analysis (PLS-DA).
Partial Least Squares regression (PLS) is used for pattern
recognition between two matrices, for example, X and Y
(19); in the present case, X corresponds to the individual
T-RFs, and Y denotes the diagnosis (RAS versus con-
trols, major RAS versus minor RAS). The variables are
plotted along an orthogonal axis. The importance of each
X-variable to the Y-variable is presented as column bars
in a corresponding column loading plot. The final PLS-
DA loading column plots in the results section are models
based on X-variables with Variable Influence of Projec-
tion (VIP) values ]1. These VIP-values can be used to
discriminate between important and unimportant predic-
tors for the overall model. X-variables with VIP- values
]1 were kept while those with lower VIP-values were
discarded. The quality of the multivariate analysis was
assessed based on the parameters R2Y, that is, how well
the variation of the Y-variable is explained by the model,
and Q2, that is, how well a variable can be predicted by
the model. Univariate data analysis was performed on,
according to the SIMCA analysis, relevant X-variables
using Fisher’s exact test (GraphPad Prism 6 software;
GraphPad Inc., San Diego, CA). A P50.05 was con-
s i d e r e dt ob es t a t i s t i c a l l ys i g n i f i c a n t( * P50.05; ** P50.01).
Adjustment for mass-significances was not performed,
since the univariate analysis was based on SIMCA results
where only the most important peaks were further
analysed.
Diversity within a bacterial community can be de-
scribed using the concepts of ‘richness’ (the total number
of peaks, each peak reflecting a bacterial taxon) and
‘evenness’ (the peak size, reflecting the amount of each
taxon). Shannon’s Index ðH ¼ 
P
S
i¼1piInpiÞ was used to
estimate the diversity (richness and evenness). This index
quantifies the uncertainty regarding the species identityof
an individual who is picked at random from the dataset
(20). A high value of H represents a diverse and equally
distributed bacterial community, whereas a low value
characterises a bacterial community with lower levels
of diversity. A value of 0 represents a community with
just one taxon. Evenness within a group was calculated
with Shannon’s Evenness Index (E H/lnS), where E
assumes a value between 0 and 1 and where 1 represents
complete evenness. S equals the total number of species,
and pi corresponds to the proportion of S made up of
the ith species in the community. Univariate data analysis
was performed using Mann-Whitney U-test (GraphPad
Prism 6 software).
Results
Bacterial diversity in the oral microbiota is similar in
patients with RAS and control subjects
The richness (the total number of T-RFs reflecting the
number of different taxa within the community) and
evenness (diversity including a measure of T-RF size,
reflecting the relative amount of each different taxon) of
the buccal microbiota are indicators of bacterial diversity.
The richness of the microbiota of an individual was
estimated by counting the number of T-RFs detected for
that particular individual. In total, 192 different T-RFs
could be identified within the 120 individuals, 156 were
identified in the control group and 118 in the RAS group.
While 82 species were common to both groups, 74 were
found exclusively in the control group and 36 exclusively
in the RAS group. The richness showed no differences
between the RAS and control groups (median values of
12 and 11 peaks, respectively) (Fig. 1b). The same pattern
was observed for diversity estimated with the Shannon’s
index (Fig. 1c). There was a tendency towards a higher
Shannon’s Evenness Index in the patients with RAS than
inthecontrolsubjects(P  0.06)(Fig.1d),suggestingthat
variation in population levels between different taxa is
lower within the RAS group than the control group.
Differences in oral microbiota compositions between
patients with RAS and control subjects
A multivariate analysis was performed to compare the
buccal microbiota of the patients with RAS and control
subjects using a PLS-DA. The results are illustrated in a
3D-score scatter plot (Fig. 2a). The relationships between
the X-variables, that is, the buccal microbiota (identified
as T-RFs), and the Y-variable (i.e. the diagnosis of
RAS or control subject) are depicted. The patients with
RAS were clustered, indicating similarities in their buccal
microbiotas, whereas the controls were separate from
the patients, indicating a different microbiota profile.
The related column-loading plot reveals the T-RFs that
contributed to the difference between the two groups
(Fig. 2b). Only the X-variables of significance for the
model, that is, VIP values ]1, are projected. These
are the X-variables that make the largest contribution
to the separation. The X-variables that showed little
or no difference between the two groups were assigned
VIP-values 51 (Supplementary Fig. 1). These variables
were therefore excluded, as they did not contribute to
the separation of the two groups.
As shown in the column-loading plot (Fig. 2b) several
peaks were associated with the patients with RAS and
others were associated with the controls. These peaks
were selected and subjected to univariate analysis (Fig. 3).
Peaks 60 and 489 were more prevalent within the buccal
microbiota of the patients with RAS than in the controls
(P 0.04 and P 0.03, respectively) (Fig. 3a and b).
Oral microbiota of patients with RAS
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(page number not for citation purpose)Whereas peak 58 was associated with the controls, as
none of the patients with RAS presented with this peak
(P 0.03) (Fig. 3c). A tendency toward a difference was
noted for peak 490 (P 0.06) (Fig. 3d), which was more
frequently observed in the control subjects than in the
patients with RAS.
Differences in the oral microbiota persist when the
patients with RAS are divided into subgroups
The patients with RAS were categorised according to
lesion size (major RAS/minor RAS), presence of lesion
when sampling (RAS Lesion/RAS No Lesion), and
whether or not they were on a regular medication (RAS
Fig. 2. Multivariate analysis reveals differences in the oral microbiota between patients with recurrent aphthous stomatitis
(RAS) and control subjects. (a) The Partial Least Squares-discriminant analysis (PLS-DA) 3D-score scatter plot depicts the
relationship between the X-variables, that is, the buccal microbiota (identiﬁed as Terminal-Restriction Fragment Length
Polymorphism (T-RFLP) peaks) and the Y-variables, that is, the study population (patients with RAS and control subjects).
Each symbol represents the peak pattern of a single individual. Individuals with similar buccal microbiotas cluster together,
whereas individuals with different microbiotas are separated. (b) A column-loading plot depicting only the X-variables that are
of signiﬁcance for the model, that is, having Variable Inﬂuence of Projection (VIP) values ]1. X-variables projected on the same
side are associated with Y-variables, and X-variables projected on the opposite side are inversely associated with Y. The closer
the X-variable is to the Y-variable, the higher the bar and the lower the spread, therefore the stronger the association. R2Y
indicates how well the variation of Y is explained, while Q2 indicates how well Y can be predicted. For this model: R2Y 0.33
and Q2 0.21.
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if the observed differences in the buccal microbiota, bet-
ween the patients with RAS and controls, were in any
way linked to these parameters. For this purpose, we
compared the buccal microbiota of the subdivided
patients with RAS to controls by a PLS-DA analysis.
The results are illustrated in the 3D-score scatter plot
(Fig. 4). The patients with RAS clustered together, which
indicates similarities in their buccal microbiotas, whereas
the controlswereseparated from the patients, demonstrat-
ing a different microbial pattern. The patients who had
lesions at the time of sampling clustered furthest away
from the controls, indicating that their oral microbiotas
differed the most from the controls. The patients with
major RAS lesions clustered further away from the
controls than the patients with minor lesions. Hence,
patients with major RAS that had lesions at time of
sampling clustered furthest from the controls, whereas
patients with minor RAS that did not have lesions at the
time of sampling clustered closest to the controls. Further
subdivision, taking into account the usage of medication,
was not performed since the number of patients became
too low.
The three T-RFs, present in the patients with RAS that
differentiated from the controls (60, 489, and 490; Fig. 3),
were studied according to their presence in the different
RAS patient subgroups (Fig. 5). Peaks 60 and 489 were
both detected more frequently in patients who presented
with a lesion upon sampling, as compared with patients
who lacked lesions. These two peaks also tended to be
present more often in patients with minor RAS lesions
and in patients who did not receive medication. In
contrast, peak 490 was less prevalent in the patients
with RAS who presented with a lesion upon sampling
as compared to controls. This peak was also less often
found in the patients with RAS who had minor lesions as
compared to patients with major RAS lesions or to
controls and in patients who did not receive medication
compared to controls.
Identification of RAS-associated bacterial species
T-RFLP does not yield immediate information with
regards to the genus/species identity. Such information
can be obtained by comparison of observed T-RFs with
theoretical sizes acquired by in silico digestion. This
method calculates, from known restriction cleavage sites
in a particular species, the sizes of the fragment that
should be generated. We used this methodology to analyse
whether the three species, S. sanguinis, H. pylori and S.
oralis were present in the microbiota and, if so, differed in
abundance between the patients with RAS and controls
as suggested by previous studies (2, 5, 7). H. pylori was
calculated to generate a fragment of 270 272 bp, S. oralis
gave fragments of 549 bp or 553 bp, and S. sanguinis
gave fragments of 545, 546, 548, 555 or 557 bp. T-RFs
corresponding to these fragment lengths were not found
to be relevant in our model separating patients with RAS
from control subjects based on microbiota composition.
Discussion
RAS takes different clinical forms and may be present
either on its own or as part of a broad spectrum of
systemic disorders (21). Currently, it is unclear if RAS
qualifies as a disease per se or is merely a manifestation
of different underlying systemic disorders. Thus, RAS
may be considered as a pathological reaction pattern of
the oral mucosa rather than as a specific disease.
The present study focuses on the commensal oral mic-
robiota as a potential aetiological factor in RAS, by
sampling the buccal mucosa. Previous studies have indi-
cated that the oral microbiota in the healthy oral cavity
differs from thatobservedinvariousoraldiseases (22 26).
The oral microbiota seems to be more stable both within
and between individuals, than microbes colonising other
niches within the body (27). Using T-RFLP, we found
suggestive evidence of differences in oral microbiota
profiles of patients with RAS and healthy age- and
gender-matched controls. Certain T-RFs were more
Fig. 3. Patients with recurrent aphthous stomatitis (RAS)
have an altered prevalence of certain bacterial genus/species
in their oral mucosa, as compared to control subjects. (a d)
Four relevant peaks, 58, 60, 489 and 490, were identiﬁed in
the multivariate analysis as differentiating between patients
with RAS and control subjects. These peaks were selected
for further statistical analysis with Fisher’s exact test
(*P50.05). Each bar represents the proportion of indivi-
duals within the group that have the indicated peak.
Oral microbiota of patients with RAS
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T-RFs showed the opposite pattern. Differences were
also evident when the patients with RAS were further
subdivided on the bases of presenting with a lesion upon
samplingandtheactualsizeofthelesion.Themicrobiotas
of the patients differed to the greatest extent from those
of the controls when a lesion was present at the time of
sampling, although the buccal swab was not applied to
the lesion itself.
Several different bacterial species have been associated
with RAS. Since the study by Barile et al. (2) additional
studies have supported a possible relationship between
S. sanguinis 2A and this condition (28 30). However,
conflicting results have been reported (31, 32) and a
direct association has therefore not been confirmed.
H. pylori has been found in RAS ulcers and implicated
in the aetiology (7, 33). The effect of eradication of this
bacterium during the clinical course of RAS has been
studied with positive results (34, 35). However, other
studies (36 38) have failed to find an association between
H. pylori infection and RAS or other oral mucosal
lesions, indicating that this bacterium is not to be of
aetiological significance for the development of RAS.
Theresultofthisstudyindicatesthateitherthepresence
of a lesion alters the microbiota of the entire oral cavity or
that a changed microbiota triggers the development of
lesions.To resolvethis issue,further studies arerequiredin
which the patients are followed for a longer period of time
to study the microbiota at different intervals both during
the presence of lesions and between episodes of lesions.
It is also important to acknowledge possible differences in
the resident bacterial species within and outside of the
lesions. This approach enables to elucidate the extent to
whichthemicrobiotaofthelesionsaffectthenon-inflamed
tissue and vice versa. The multivariate analysis suggests
that there are differences in the buccal microbiotabetween
patients with minor and major RAS, that is, different
lesion sizes. However, as lesionswere more frequently seen
intheminorRASgroupatthetimeofsampling,wecannot
exclude the possibility that the differences observed
between these two groups were simply due to the presence
orabsenceofalesion.Therefore,alargerstudypopulation
is required. Nevertheless, we can conclude from the
present study that the presence of lesions has greater
impact on microbiota composition than the actual size of
the ulcer. It is reasonable to assume that certain types of
Fig. 4. Multivariate analysis reveals that the presence of lesions during sampling, contributes to the observed differences in oral
microbiotabetween patients with recurrent aphthous stomatitis (RAS) and control subjects. The patients with RAS were divided
into subgroups based on: 1) the size of the lesion (minor RAS B10 mm and major RAS ]10 mm), and 2) presenting with or
not presenting with a lesion at the time of sampling (RAS Lesion/RAS No Lesion). A Partial Least Squares-discriminant
analysis (PLS-DA) 3D-score scatter plot depicts the relationship between the X-variables, that is, the buccal microbiota
(identiﬁed as Terminal-Restriction Fragment Length Polymorphism (T-RFLP) peaks) and the Y-variables, that is, the study
population (identiﬁed as minor RAS patients with and without lesions, major RAS patients with and without lesions, and
control subjects). Each symbol represents the peak pattern of one individual. Individuals with similar buccal microbiotas cluster
together, whereas individuals that have different microbiotas are separated. The six major RAS patients for whom it was not
known if they presentedwith a lesion upon sampling or not were excluded from this part of the analysis. R2Y indicates how well
the variation of Y is explained, while Q2 indicates how well Y can be predicted. For this model: R2Y  0.35 and Q2  0.03.
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the oral bacterial community. However, as we did not
observe any large differences between the patients on
medications and those who had no prescribed medica-
tions, we exclude medication as a confounding factor.
A gut microbiota of low diversity during early infancy
is known to be a risk factor for the development of
allergy (39 41). Therefore, we investigated whether low-
level diversity of the buccal microbiota is related to
RAS. We found no differences in microbiota richness at
the individual level between the patients with RAS and
the control subjects. Therefore, a low level of complexity
of the oral microbiota does not seem to underlie the
aetiology of RAS. However, at the group level, fewer
bacterial species were represented in the RAS patient
group than in the equally sized control group (118 species
versus 156 species). Accordingly, 74 species were found
exclusively in the control group, whereas only 36 species
were found exclusively in the patients with RAS.
The T-RFLP methodology was chosen because it is
an excellent method for fingerprinting the microbiota
and revealing overall differences in microbiota pattern.
However, a limitation is its inability to identify genus/
species that generate a particular T-RF. Databases are
needed that allow conversions of each T-RF size to a
genus/species. To identify genus composition, additional
molecular-based methods are required, e.g. cloning and
sequencing of the 16S rRNA genes. However, these
Fig. 5. The differences in oral microbiota between patients with recurrent aphthous stomatitis (RAS) and control subjects are
most prominent in the patients who had lesions during sampling. Peaks 60, 489, and 490 were also found to be of importance in
the multivariate analysis when patients with RAS were further divided into the subgroups: minor and major RAS (minor
RASB10 mm and major RAS ]10 mm), Lesion and No Lesion (RAS Les/RAS No Les) and Medication and No Medication
(RAS Med/RAS No Med). They were further analysed statistically with Fisher’s exact test (*P50.05, ** P50.01). Each bar
represents the proportion of individuals within the group that has the indicated peak.
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sample sizes. The T-RF size of a known bacterium can
be calculated based on knowledge of the specific enzyme
digestionsite(‘insilico’simulation).However,thisstrategy
is not suitable for unknown bacteria, since different
species of bacteria may generate the same T-RFs of
identical or near identical size. In addition, a discrepancy
between the actual peak size and the observed experi-
mental peak size has previously been reported (15, 42).
High-throughput sequencing, such as pyro-sequencing,
has greatly facilitated the sequencing of genomes. How-
ever, it is currently expensive to conduct this type of study
with a large number of samples. Furthermore, bacterial
identification, based on the 16S rRNA gene, remains a
challenge,sincebacteriawithaclosephylogeneticrelation-
ship cannot be separated, e.g. the various Streptococcus
species that dominate the microbiota in the human oral
cavity that are highly similar at the 16S rRNA sequence
level.
We have assessed the microbiota of the buccal mucosa
rather than that of the ulcer itself, which has been the
main focus in previous studies. The rationale for this
approach was our belief that it is more relevant to study
the preconditions for the development of RAS than
studying the effect of inflammation in already established
ulcerations. Further research using larger cohorts, in
which the patients are allocated so as to create more
homogenous subgroups, are required to reveal the role
of the oral microbiota in this complex condition.
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